- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Severe Crohn disease; moderate to severe ulcerative colitis; Severe active juvenile idiopathic arthritis; Complex refractory fistulising Crohn disease; Severe active rheumatoid arthritis; Severe psoriatic arthritis; Ankylosing spondylitis; Severe chronic plaque psoriasis; Moderate to severe hidradenitis suppurativa
- Meeting Date: July 2023
- Public Summary Document (PSD) July 2023 PBAC Meeting - (PDF 338KB)
- Public Summary Document (PSD) July 2023 PBAC Meeting - (Word 48KB)
Adalimumab – July 2023
Adalimumab: Injection 40 mg in 0.4 mL pre-filled pen, Injection 40 mg in 0.4 mL pre-filled syringe, Injection 80 mg in 0.8 mL pre-filled syringe; Ardalicip®
Last updated
27 October 2023